Mandate

Vinge advises Main Capital and Aritma in connection with the acquisition of Programekonomi

Vinge has advised Aritma International AS (“Aritma”), a Norwegian bank-connectivity and financial automation software provider, in connection with the acquisition of Programekonomi Svenska Aktiebolag.

The acquisition is expected to complement and expand Aritma’s offering and are aligned with Aritma’s continued expansion strategy in the Nordic financial automation and ERP connectivity market, thereby further strengthening the group’s position in the Nordic region.

Programekonomi Svenska Aktiebolag is a software company that provides Swebase, an extension for Microsoft Business Central, that enhances business and decision-making processes in Microsoft Business Central by providing companies features such as bank file handling, document management and improved security. Through the acquisition, Aritma complements its solutions for bank integration and financial automation, while broadening its offering within Microsoft Business Central with both product and consulting expertise.

Vinge’s team consisted of Filip Öhrner, Olivia Altheden, Alex Forsberg, Nora Karlsson (M&A), Alice Göransson (employment) and Ian Jonson (IPR).

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025